A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
← catalyst calendarNCT07491172 · readout ≤ 315 d
Sponsored by CRISPR Therapeutics AG (industry) · CRSP — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
90estimated
Sites
19
Countries
Australia, New Zealand, United Kingdom +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-21 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cardiovascular
- Metabolic Disease
- Dyslipidemias
- Lipid Disorder
- Hypertriglyceridemia
- Heterozygous Familial Hypercholesterolemia (HeFH)
- Homozygous Familial Hypercholesterolemia (HoFH)
- Severe Hypertriglyceridemia (sHTG)
- Mixed Hyperlipemia
- Hypercholesterolaemia
Intervention
- Drug: CTX310
Primary outcome
what the primary-completion date above is the date OFTo evaluate the safety of CTX310 in adult subjects with dyslipidemias that are refractory to available treatments
measured From CTX310 infusion up to 12 months
Permalink · CRSP's whole pipeline · Catalyst calendar · Every registered study · What changed